These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

843 related items for PubMed ID: 21204103

  • 1. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
    Smolen JS, Aletaha D.
    Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.
    Schoels M, Alasti F, Smolen JS, Aletaha D.
    Arthritis Res Ther; 2017 Jul 04; 19(1):155. PubMed ID: 28676129
    [Abstract] [Full Text] [Related]

  • 3. Assessing remission in clinical practice.
    Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS.
    Rheumatology (Oxford); 2007 Jun 04; 46(6):975-9. PubMed ID: 17341506
    [Abstract] [Full Text] [Related]

  • 4. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study.
    Burmester GR, Ferraccioli G, Flipo RM, Monteagudo-Sáez I, Unnebrink K, Kary S, Kupper H.
    Arthritis Rheum; 2008 Jan 15; 59(1):32-41. PubMed ID: 18163417
    [Abstract] [Full Text] [Related]

  • 5. DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt.
    Martins FM, da Silva JA, Santos MJ, Vieira-Sousa E, Duarte C, Santos H, Costa JA, Pimentel-Santos FM, Cunha I, Cunha Miranda L, Nóvoa T, Cruz M, Bernardes M, Araujo D, Pereira Silva JA, Silva JC, Branco JC, Gomes JA, Faustino A, Fonseca JE, Canhão H.
    Rheumatology (Oxford); 2015 Feb 15; 54(2):286-91. PubMed ID: 25173347
    [Abstract] [Full Text] [Related]

  • 6. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS, Aleksandrova EN, Novikov AA, Cherkasova MV, Panasyuk EY, Nasonov EL.
    Ter Arkh; 2013 Feb 15; 85(5):24-9. PubMed ID: 23819335
    [Abstract] [Full Text] [Related]

  • 7. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
    Izumi K, Kaneko Y, Hashizume M, Yoshimoto K, Takeuchi T.
    PLoS One; 2015 Feb 15; 10(12):e0145468. PubMed ID: 26698858
    [Abstract] [Full Text] [Related]

  • 8. Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.
    Aletaha D, Wang X, Zhong S, Florentinus S, Monastiriakos K, Smolen JS.
    Semin Arthritis Rheum; 2020 Apr 15; 50(2):276-284. PubMed ID: 31590930
    [Abstract] [Full Text] [Related]

  • 9. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
    Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Yamasaki S, Nakamura H, Ueki Y, Migita K, Mizokami A, Origuchi T, Aoyagi K, Eguchi K.
    Mod Rheumatol; 2011 Aug 15; 21(4):365-9. PubMed ID: 21229375
    [Abstract] [Full Text] [Related]

  • 10. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
    Wechalekar MD, Lester S, Proudman SM, Cleland LG, Whittle SL, Rischmueller M, Hill CL.
    Arthritis Rheum; 2012 May 15; 64(5):1316-22. PubMed ID: 22135142
    [Abstract] [Full Text] [Related]

  • 11. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
    Barnabe C, Homik J, Barr SG, Martin L, Maksymowych WP.
    J Rheumatol; 2014 Aug 15; 41(8):1607-13. PubMed ID: 25028371
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study.
    Nishimoto N, Takagi N.
    Mod Rheumatol; 2010 Dec 15; 20(6):539-47. PubMed ID: 20617358
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level.
    Funahashi K, Koyano S, Miura T, Hagiwara T, Okuda K, Matsubara T.
    Mod Rheumatol; 2009 Dec 15; 19(5):507-12. PubMed ID: 19609487
    [Abstract] [Full Text] [Related]

  • 17. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Smolen JS, Szumski A, Koenig AS, Jones TV, Marshall L.
    Arthritis Res Ther; 2018 Jan 16; 20(1):8. PubMed ID: 29338762
    [Abstract] [Full Text] [Related]

  • 18. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ.
    Arthritis Rheum; 2008 Oct 16; 58(10):2968-80. PubMed ID: 18821691
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.